Decrease in naturally occurring antibodies against epitopes of Alzheimer’s disease (AD) risk gene products is associated with cognitive decline in AD

Table 4 Assessment of diagnostic utility of each panel by ROC analysis

Category	Term description	Matching proteins in network	CN vs. AD		CN vs. MCI
Category	Term description	Matching proteins in network	AUC (95% CI)	Sensitivity^{against 95% specificity}	AUC (95% CI)	Sensitivity^{against 95% specificity}
Total	Total 17 NAbs	17 NAbs	0.975 (0.947–1.000)	0.926	1.000 (1.000–1.000)	1.000
GO process	Glial cell proliferation	CLU, TREM2, PTK2B	0.914 (0.862–0.965)	0.685	0.885 (0.798–0.972)	0.500
GO process	Regulation of neurofibrillary tangle assembly	SORL1, CLU	0.821 (0.742–0.900)	0.554	0.872 (0.776–0.968)	0.500
GO process	Integrin-mediated signaling pathway	ADAM10, ADAMTS1, FERMT2, PTK2B	0.782 (0.699–0.865)	0.429	0.675 (0.540–0.810)	0.250
DISEASES	Alzheimer’s disease	SORL1, ADAM10, CLU, TREM2	0.929 (0.884–0.973)	0.722	0.916 (0.843–0.989)	0.688
DISEASES	Neurodegenerative disease	SORL1, ADAM10, CLU, TREM2, WWOX	0.928 (0.883–0.973)	0.759	0.942 (0.888–0.996)	0.750
DISEASES	Amyloidosis	SORL1, ADAM10, CLU	0.838 (0.764–0.912)	0.518	0.877 (0.786–0.968)	0.500

NAbs natural antibodies, AD Alzheimer’s disease, MCI mild cognitive impairment, CN cognitively normal controls, ROC receiver operating characteristic, AUC area under the curve

ISSN: 1742-2094